Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for ONS-5010/LYTENAVA™ (bevacizumab-vikg)


https://www.channelchek.com/news-channel/Release___Outlook_Therapeutics__OTLK____Completes_Patient_Enrollment_of_Open_Label_Safety_Study_for_ONS_5010_LYTENAVA__bevacizumab_vikg_